title: Prevention of epilepsy by taurine treatments in mice experimental model.
abstract: An experimental model based on kainic acid (KA) injections replicates many phenomenological features of human temporal lobe epilepsy, the most common type of epilepsy in adults. Taurine, 2-aminoethanesulfonic acid, present in high concentrations in many invertebrate and vertebrate systems, is believed to serve several important biological functions. In addition, it is believed to have a neuroprotective role against several diseases. In the present study, an experimental mouse model based on taurine pretreatment prior to KA administration has been improved to study whether taurine has a neuroprotective effect against KA-induced behavior and cell damage. Under different treatments tested, taurine's most neuroprotective effects were observed with intraperitoneal taurine injection (150 mg/kg dosage) 12 hr before KA administration. Thus, a reduction in or total absence of seizures, together with a reduction in or even disappearance of cellular and molecular KA-derived effects, was detected in mice pretreated with taurine compared with those treated only with KA. Moreover, the use of tritiated taurine revealed taurine entry into the brain, suggesting possible changes in intracellular:extracellular taurine ratios and the triggering of pathways related to neuroprotective effects.
authors.affiliation: Departament de Biologia Cel.lular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Junyent
authors.forename: J
authors.initials: J
authors.lastname: Utrera
authors.forename: R
authors.initials: R
authors.lastname: Romero
authors.forename: M
authors.initials: M
authors.lastname: Pallàs
authors.forename: A
authors.initials: A
authors.lastname: Camins
authors.forename: D
authors.initials: D
authors.lastname: Duque
authors.forename: C
authors.initials: C
authors.lastname: Auladell
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002154:Calpain / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D004827:Epilepsy / Q000139:chemically induced / Q000517:prevention & control*; D015151:Immunoblotting; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D007608:Kainic Acid; D008297:Male; D051379:Mice; D009457:Neuroglia / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control; D013654:Taurine / Q000008:administration & dosage / Q000032:analysis / Q000097:blood / Q000494:pharmacology*
chemical_list: D000927:Anticonvulsants; D018696:Neuroprotective Agents; D016760:Proto-Oncogene Proteins c-fos; D013654:Taurine; D002154:Calpain; D007608:Kainic Acid